Last updated: 2026-09-05 22:20:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Jade Biosciences, Inc. (JBIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $19.92, with a market capitalization of $1.36B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.91 to $28.00. This page covers its latest market performance, valuation, price trends and company information.
$1.36B | |
$19.86 | |
$28.00 | |
$6.57 | |
$19.85 | |
537.92K | |
-- | |
-- | |
$28.00 | |
$6.91 | |
-- | |
-- |
Jade Biosciences, Inc. (JBIO) last closed at $19.85 as of 2026-09-04 23:31:00, unchanged from the previous close of $19.85.
During the latest regular trading session, JBIO traded between $6.57 and $28.00, with a volume of 537.92K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Jade Biosciences, Inc. (JBIO) moved from $20.65 to $19.92, representing a decline of 3.55% ($0.73).
The stock traded between $19.47 and $21.02 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 649.60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 61.7%
JBIO is currently trading at $19.92, placing it 61.7% of the way from its 52-week low of $6.91 to its 52-week high of $28.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jade Biosciences, Inc. (JBIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.